Arnold & Porter Advises Corstasis Therapeutics on Acquisition by Esperion — $75M Upfront, Up to $180M in Milestone Payments

"Arnold & Porter advised privately held, commercial-stage Corstasis Therapeutics on a definitive agreement to be acquired by publicly traded Esperion Therapeutics. Esperion, through a subsidiary, will pay $75 million upfront for all outstanding Corstasis stock, with up to $180 million in additional milestone payments plus royalties on certain product sales; the deal is expected to close in Q2 2026, subject to customary conditions. The Arnorld & Porter team was led by Lowell Dashefsky and partner Wayne Janke."

Arnold & Porter advised Corstasis Therapeutics Inc. in its sale to Esperion Therapeutics, Inc. Under the agreement, Esperion, through a subsidiary, will acquire all outstanding Corstasis stock for an upfront payment of $75 million in cash, with Corstasis shareholders eligible to receive up to an additional $180 million upon achievement of certain regulatory and commercial milestones, plus royalties on sales of certain products; the transaction is expected to close in the second quarter of 2026, subject to customary closing conditions. Participating lawyers from Arnold & Porter named in the release: - Lowell Dashefsky — co-head of the firm’s Private Equity and Life Sciences Transactions practices. - Wayne Janke — partner (practice area not specified in the press release).

Menu

Arnold & Porter Advises Corstasis Therapeutics on Acquisition by Esperion — $75M Upfront, Up to $180M in Milestone Payments

Read the full story

Menu

Arnold & Porter Advises Corstasis Therapeutics on Acquisition by Esperion — $75M Upfront, Up to $180M in Milestone Payments

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads